Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have ...
Moderna’s messenger RNA vaccine for respiratory syncytial virus (RSV) is now FDA approved, a regulatory decision that comes nearly a year after GSK and Pfizer won regulatory approvals for ...
Moderna’s shot is the third RSVvaccine for people 60 and older that’s gotten the green light from the FDA and the first mRNA vaccine among them. It’s the company’s second product to ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virusvaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second ...